Martinod
Kimberly Martinod, Cambridge, MA US
Patent application number | Description | Published |
---|---|---|
20140199329 | METHODS FOR TREATING AND PREVENTING NEUTROPHIL-DERIVED NET TOXICITY AND THROMBOSIS - Embodiments of the technology described herein are based upon the discoveries that neturophil extracellular traps (NETs) provide a stimulus for thrombus formation and that NETs are present in stored blood products. Accordingly, some embodiments relate to methods of treating and preventing toxicity of NETs and thrombosis caused by NETs. Additional embodiments are directed towards methods of treating stored blood products to prevent transfusion-related injuries. | 07-17-2014 |
Laurent Martinod, Le Chesnay FR
Patent application number | Description | Published |
---|---|---|
20080273630 | DECODING SYMBOLS OF A SIGNAL DISTRIBUTED ACCORDING TO FREQUENCY AND TIME DIMENSIONS - A signal of OFDM type received in a radio receiver via a propagation channel includes symbols distributed according to frequency and time. The receiver determines likelihoods of the symbols, decodes the received signal to yield a decoded signal as a function of the likelihoods of the symbols, and estimates an instantaneous noise power of the received signal as a function of a difference between the received signal and a reconstructed noise-free signal derived from the decoded signal. A filtering module determines a bounded distribution of the instantaneous noise power as a function of frequency and/or time, and filters the distribution to yield a filtered noise variance as a function of a frequency and/or time parameter of the propagation channel. A corrector weights the likelihoods of the symbols of the received signal to be decoded as a function of the filtered noise variance. | 11-06-2008 |
20100322339 | REDUCTION OF INTERFERENCE IN AN OFDM SIGNAL WITH WEIGHTING VECTORS EVOLVING IN VECTOR SUBSPACES - To reduce interferences in signals received by a receiver through a propagation channel, each including symbols distributed according to frequency and time dimensions and corresponding to a common emitted signal, the receiver weights an estimate of the emitted signal and the received signals by weighting vectors evolving in vector subspaces representing time variations and frequency variations of the channels for propagating the signals between an emitter and the receiver. These vector subspaces are defined by matrices, some columns of which are suppressed as a function of frequency and time constraints of the channel. The receiver minimizes a function of the difference between the sum of weighted received signals and the weighted estimate of the emitted signal in order to estimate the emitted signal as a function of the weighting vectors and the received signals. | 12-23-2010 |
20140006895 | ERROR CORRECTION ENCODING METHOD, DECODING METHOD AND ASSOCIATED DEVICES | 01-02-2014 |
20140006909 | ERROR CORRECTION ENCODING METHOD, DECODING METHOD AND ASSOCIATED DEVICES | 01-02-2014 |
20140006910 | ERROR CORRECTION ENCODING METHOD, DECODING METHOD AND ASSOCIATED DEVICES | 01-02-2014 |
Laurent Martinod, Le Chesney FR
Patent application number | Description | Published |
---|---|---|
20140321584 | INTERFERENCE REDUCTION METHOD - This interference reduction method in a receiver ( | 10-30-2014 |
20140334569 | METHOD FOR ESTIMATING A RADIO CHANNEL - This method for the estimation of a channel between an emitter and a receiver, where the said emitter emits a signal comprising symbol frames distributed in time and frequency, among which pilot symbols known to the receiver, is characterised in that it comprises the following steps: •—computation ( | 11-13-2014 |
Serge Martinod, Groton, CT US
Patent application number | Description | Published |
---|---|---|
20080199491 | Sustained Release Vaccine Composition - A non-liquid vaccine composition including one or more antigen component(s); a pharmaceutically acceptable non-liquid adjuvant therefor; and optionally a non-liquid vaccine protection agent. | 08-21-2008 |
Serge R. Martinod, Groton, CT US
Patent application number | Description | Published |
---|---|---|
20110142901 | SUSTAINED RELEASE COMPOSITION - A sustained release apparatus including at least one sustained release mini-implant or pellet; the or each mini-implant or pellet including: a sustained release support material; and a pharmaceutical composition including a Luteinising Hormone Releasing Hormone (HLRH) agonist and/or antagonist component the size and/or number and/or payload of mini-implant(s) or pellet(s) providing, release of LHRH agonist and/or antagonist at, or above, a desired threshold level for treatment of a selected indication, the apparatus providing approximately zero order release of the LHRH agonist and/or antagonist. | 06-16-2011 |